Tag: press release

CUPERTINO, Calif., June 26, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced the pricing of its previously announced public offering with existing and new healthcare focused institutional investors for the purchase and sale of 20,000,000 shares of its common stock (or common stock equivalents in lieu thereof) together with Series C warrants to purchase up to 20,000,000 shares of common stock (the "Series C Warrants") and Series D warrants to purchase up to 20,000,000 shares of common stock (the "Series D Warrants"), at a combined offering price of $0.50 per share and accompanying warrants, for aggregate gross proceeds of approximately $10 million before deducting placement agent fees and other offering expenses.

THORNTON, Colo., June 26, 2025 (GLOBE NEWSWIRE) -- Ascent Solar Technologies (Nasdaq: ASTI) (“Ascent” or the “Company”), the leading U.S. innovator in the design and manufacture of featherweight, flexible, and durable CIGS thin-film photovoltaic (PV) solutions, announced today that the company is commencing work on a Collaborative Agreement Notice (CAN) with NASA Marshall Space Flight Center (MSFC) and support from NASA Glenn Research Center (GRC) to efficiently advance capabilities for receiving beamed power using CIGS PV modules.

~ Palomar to Appoint Neptune as Exclusive Managing General Agent for Flood Insurance ~

Each party to offer Palladyne™AI’s embodied neuro-symbolic artificial intelligence Software bundled with Mobilicom’s OS3 cybersecurity solution

LEHI, Utah, June 26, 2025 (GLOBE NEWSWIRE) -- Nature’s Sunshine Products, Inc. (NASDAQ: NATR) (“Nature’s Sunshine” or the “Company”), a leading manufacturer of high-quality herbal and nutritional supplements, today announced the pricing of an underwritten secondary public offering of up to 2,854,607 shares of its common stock to be sold by Fosun Pharma USA, Inc (the “Selling Stockholder”). The shares of common stock are being sold at a price of $12.00 per share. The offering is expected to close on June 27, 2025, subject to customary closing conditions.

NEW YORK, June 26, 2025 (GLOBE NEWSWIRE) -- FTAI Aviation Ltd. (NASDAQ: FTAI; the "Company" or “FTAI”) plans to announce its financial results for the second quarter 2025 after the closing of Nasdaq on Tuesday, July 29, 2025. A copy of the press release and an earnings supplement will be posted to the Investor Relations section of the Company's website, https://www.ftaiaviation.com/.